IMMUNITYBIO, INC. Cash and Cash Equivalents, Period Increase (Decrease)
IMMUNITYBIO, INC. (IBRX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $15.79 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-12
- IMMUNITYBIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $2.95M.
- IMMUNITYBIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$18.12M.
- IMMUNITYBIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $25.44M.
- IMMUNITYBIO, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $5.51M.
- IMMUNITYBIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $15.79M.
- IMMUNITYBIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$167.82M, a 243.68% decline from fiscal 2015.
- IMMUNITYBIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $116.80M, a 98.80% increase from fiscal 2014.
- IMMUNITYBIO, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $58.75M, a 25008.55% increase from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$15.17M derived: sum of 2 quarters · filed 2018-03-12 | $10.28M derived: sum of 3 quarters · filed 2018-03-12 | $15.79M 10-K · filed 2018-03-12 |
| 2017-09-30 | -$18.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $7.32M derived: sum of 2 quarters · filed 2017-11-07 | $12.84M 10-Q · filed 2017-11-07 | -$10.48M derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-06-30 | $25.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $30.96M 10-Q · filed 2017-08-07 | $7.63M derived: sum of 3 quarters · filed 2018-03-12 | $816.00K derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-03-31 | $5.51M 10-Q · filed 2017-05-08 | -$17.81M derived: sum of 2 quarters · filed 2018-03-12 | -$24.63M derived: sum of 3 quarters · filed 2018-03-12 | -$49.65M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-12-31 | -$23.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$30.14M derived: sum of 2 quarters · filed 2018-03-12 | -$55.17M derived: sum of 3 quarters · filed 2018-03-12 | -$167.82M 10-K · filed 2018-03-12 |
| 2016-09-30 | -$6.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$31.85M derived: sum of 2 quarters · filed 2017-11-07 | -$144.50M 10-Q · filed 2017-11-07 | -$327.21M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | -$25.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$137.69M 10-Q · filed 2017-08-07 | -$320.39M derived: sum of 3 quarters · filed 2018-03-12 | -$82.21M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | -$112.66M 10-Q · filed 2017-05-08 | -$295.37M derived: sum of 2 quarters · filed 2018-03-12 | -$57.19M derived: sum of 3 quarters · filed 2018-03-12 | $13.40M derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | -$182.71M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $55.47M derived: sum of 2 quarters · filed 2018-03-12 | $126.05M derived: sum of 3 quarters · filed 2018-03-12 | $116.80M 10-K · filed 2018-03-12 |
| 2015-09-30 | $238.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $308.76M derived: sum of 2 quarters · filed 2016-11-10 | $299.51M 10-Q · filed 2016-11-10 | $355.44M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $70.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $61.33M 10-Q · filed 2016-08-15 | $117.26M derived: sum of 3 quarters · filed 2017-03-15 | $116.45M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | -$9.25M 10-Q · filed 2016-05-16 | $46.67M derived: sum of 2 quarters · filed 2017-03-15 | $45.86M derived: sum of 3 quarters · filed 2017-03-15 | |
| 2014-12-31 | $55.92M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $55.11M derived: sum of 2 quarters · filed 2017-03-15 | $58.75M 10-K · filed 2017-03-15 | |
| 2014-09-30 | -$812.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $2.83M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $3.64M 10-Q · filed 2015-09-10 | |||
| 2013-12-31 | $234.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |